National Institutes of Health

Description

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July, 2002 for the purpose of identifying genes predisposing to IBD.Since its establishment, the IBDGC, in collaboration with other international IBD genetics consortia, has identified more than 100 such susceptibility loci.However, many susceptibility genes still remain to be identified, and the work of elucidating how IBD risk-associated genetic variants influence the pathophysiology of IBD has barely begun.The purpose of this FOA is to renew the IBDGC to continue the discovery of susceptibility variants, and to integrate genomic with epigenomic, transcriptomic, proteomic, metabolomic, and other -omic methodologies to elucidate the effects of genetic risk variants on the pathophysiology of IBD.The GRCs will serve as sites of enrollment of IBD patients, relatives, and healthy controls for these studies, and for laboratory-based studies on biological samples taken from these subjects.The PD(s)/PI(s) of the GRCs will serve as members of the Steering Committee of the IBDGC, which will be responsible for all of the IBDGC's operational decisions, which will be binding upon all of the IBDGC's members.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV